SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects

Area of Science:

• Oncology
• Developmental Biology
• Immunology

Background:

• Embryonic development and cancer cell immune evasion are linked by immune modulatory proteins.
• Melanoma treatments often involve immune checkpoint inhibitors.
• SRY-box transcription factor 10 (SOX10) is crucial for neural crest development and melanoma growth.

Purpose of the Study:

• To investigate the immune-related targets of SOX10 in melanoma.
• To understand SOX10's role in regulating immune checkpoint proteins and anti-tumor immunity.

Main Methods:

• Investigated SOX10's regulation of herpesvirus entry mediator (HVEM) and carcinoembryonic-antigen cell-adhesion molecule 1 (CEACAM1).
• Utilized Sox10 knockout models in vivo, including immune-competent settings.
• Analyzed patient-derived cutaneous melanoma samples for correlations between SOX10 and immune pathways.

Main Results:

• SOX10 positively regulates HVEM and CEACAM1 expression.
• Sox10 knockout reduced tumor growth, especially in immune-competent models.
• Tumor growth inhibition by Sox10 knockout was partly dependent on CD8+ T cells.
• A negative correlation was observed between SOX10 and immune-related pathways in human melanoma.

Conclusions:

• SOX10 plays a significant role in melanoma immune evasion by modulating immune checkpoint proteins.
• SOX10 regulates anti-tumor immunity, with its absence impacting tumor growth and T cell responses.
• These findings suggest SOX10 as a potential therapeutic target in melanoma treatment.